TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subjects diagnosed with spontaneous parkinsonism by the United Kingdom(UK) Parkinson's Disease Society Brain Bank criteria~* subjects who are able to explain symptoms they experience and to complete relevant assessment and exams including questionaires~* subjects who understand the purpose and protocols of the study and agree to participate on the study~Exclusion Criteria:~* subjects who experience psychiatrical disorders such as cognitive or behavioral disorders~* subjects who are on prokinetics or who are unable to cease such medication~* subjects who present neurological disorders which influence gastrointestinal mobility~* subjects who present gastrointestinal conditions which influence gastrointestinal mobility~* subjects with a history of gastrectomy or colectomy~* subjects who are unable to receive and complete the course of medication due to other metabolic disorders~* subjects diagnosed with parkinson plus syndrome~* subjects who are unable to undergo MRI scan for safety reasons due to claustrophobia or certain devices such as cardiac pacemakers or aneurysm clips

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DA-9701 (Type: EXPERIMENTAL): In this arm, the study participants will receive DA-9701 30mg + placebo domperidone tablet tid ac for 4 weeks.
- Domperidone (Type: ACTIVE_COMPARATOR): (This study is a randomized, double-blinded, non-inferiority trial. Thus it is designed to have no placebo arm.) In this arm, the study participants will receive domperidone 10mg + placebo DA-9701 tablet tid ac +for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent form voluntarily.~* Histologically or cytologically documented hepatocellular carcinoma.~* BCLC stage C, and non-resectable BCLC stage B .~* At least one measurable lesion according to RECIST criteria.~* ECOG of 0 or 1.~* Adequate organ function.~* Estimated life expectancy of ≥3 months.~* For women of childbearing potential: agreement to remain abstinent; For men: agreement to remain abstinent.~Exclusion Criteria:~* Histologically or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc.~* History of hepatic encephalopathy or liver transplantation.~* Clinical significance of hydrothorax, ascites or pericardial effusion.~* Central nervous system metastases and/or carcinomatous meningitis.~* Any risk of bleeding; severe bleeding tendency or coagulation dysfunction, or under thrombolytic therapy.~* Occurred arteriovenous thromboembolic events within 6 months before the first administration.~* Tumor volume \> 50% liver volume; portal vein tumor thrombus or inferior vena cava tumor thrombus.~* Inadequately controlled arterial hypertension.~* Attack of symptomatic congestive heart failure (LVEF\<50%); History of congenital long QT syndrome.~* Known presence or history of interstitial lung disease or required hormone treatment interstitial lung disease.~* Severe infections.~* Receipt of any anti-tumor treatment, chemotherapy, targeted therapy, immunotherapy,~* Enrollment of another clinical study within 4 weeks prior to the first administration of study drugs.~* Unable to receive an enhanced CT or MRI scan of the liver.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AK104 and Lenvatinib (Type: EXPERIMENTAL): AK104 6 mg/kg IV every 2 weeks (Q2W) Lenvatinib 12mg weight≥60kg or 8mg weight\<60kg,PO QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent form (ICF) is signed and dated by the subject or legal representative. The ICF or a specific Assent form, where required, will be signed and dated by minors~* Subject has completed the Transition Period of SP0967 \[NCT02477839\] or SP0969 \[NCT01921205\] for the treatment of uncontrolled partial-onset seizures in pediatric epilepsy~* Subject is expected to benefit from participation, in the opinion of the investigator~* Subject/legal representative is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule, and medication intake according to the judgment of the investigator~* Subject is male or female aged 1 month to ≤17 years~* Subject has a diagnosis of epilepsy with partial-onset seizures~Exclusion Criteria:~* Subject is receiving any investigational drugs or using any experimental devices in addition to lacosamide (LCM)~* Subject meets a mandatory withdrawal criterion (ie, MUST withdraw criterion) for SP0967 or SP0969, or is experiencing an ongoing serious adverse event (SAE)~* For subjects ≥6 years of age, subject has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Visit 1~* Female subject who is pregnant or nursing, and/or a female subject of childbearing potential who is not surgically sterile or does not practice 1 highly effective method of contraception

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): In the first week after enrollment into EP0034 subjects will be dosed according to their weight:~* Lacosamide (LCM) 10 mg/kg/day (oral solution) for subjects weighing \<30 kg~* LCM 6 mg/kg/day (oral solution) for subjects weighing ≥30 kg to \<50 kg~* LCM 300 mg/day (tablets) for subjects weighing ≥50 kg~After 1 week the investigator may adjust the LCM dose during the Treatment Period based on clinical judgment within a range of 2 mg/kg/day to 12 mg/kg/day for the oral solution and 100 mg/day to 600 mg/day for the tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Females of non-childbearing potential~* Body mass index (BMI) 18 to 32 kg/m2, inclusive~* In good health, determined by no clinically significant findings from medical history, physical examination. 12-lead ECG, and vital signs~* Clinical laboratory evaluations, complete blood count and urinalysis within the normal range for the test laboratory, unless not deemed clinically significant by the investigator~* Negative test for drugs of abuse at screening and check-in (including alcohol)~* Negative for hepatitis B, hepatitis C and HIV infection~* Non-childbearing potential is defined as: non-pregnant, non-lactating, and either postmenopausal for at least 1 year or surgically sterile (e.g. bilateral oophorectomy and/or hysterectomy)~Exclusion Criteria:~* Significant history or clinical evidence of any metabolic (including type 1 or 2 diabetes). allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, endocrine, GI (including gastric or duodenal ulcers), Zollinger-Ellison syndrome, Barrett's esophagus, urological, neurological, or psychiatric disorder~* History of inflammatory arthritis~* History of symptomatic hypotension~* History of seizure disorders~* History of bipolar or major depressive disorder~* History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (appendectomy, hernia repair, and/or cholecystectomy will be allowed)~* History of alcoholism or drug addiction within 1 year prior to check-in~* Use of any tobacco- or nicotine-containing products within 6 months prior to check-in~* Participation in any other investigational study drug or biological agent trial in which receipt of investigational study drug occurred within 5 half-lives or 30 days, whichever is longer, prior to check-in~* Use of PPIs, H2-receptor antagonists, or antacids within 1 month prior to check-in~* History of chronic PPI use (\> 30 days of continuous daily dosing) within 6 months of check-in

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- A: Vismodegib (Type: ACTIVE_COMPARATOR): None
- B: Rabeprazole + Vismodegib (Type: EXPERIMENTAL): None
- C: Itraconazole + Vismodegib (Type: EXPERIMENTAL): None
- D: Fluconazole + Vismodegib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC - An Expansion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. With a confirmed diagnosis of AADC, including cerebrospinal fluid analysis to show reduced levels of neurotransmitter metabolites, HVA and 5-HIAA, and higher L-Dopa, or with more than one mutation within AADC gene, etc.~2. Classical clinical characteristics of AADC deficiency, such as oculogyric crises, hypotonia and developmental retardation.~3. The child patient has to be over 2 years old or a thickness of skull enough for surgery.~4. The child patient has to be under 6 years old (72 months) before being treated with study drugs.~5. Participating patients must cooperate completely for all evaluations and examinations before, during and after the whole trial.~6. Parents or guardians must sign to agree on this informed consent.~Exclusion criteria:~1. Significant brain structure abnormality determined by the physician.~2. Patients with any health or neurological doubts that may increase the risk of surgery cannot join this trial. PI has the right to evaluate the feasibility of subjects for this trial based on his/her health condition.~3. Patients with anti-AAV2 neutralizing antibody titer over 1,200 folds or an ELISA OD over 1 cannot be recruited into this trial.~4. Subjects participating in this trial cannot take any medications that may affect this clinical trial, which do not apply to those drugs used at specified duration as mentioned in this protocol.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- AAV2-hAADC (Type: EXPERIMENTAL): Dosage form: Aqueous solution Dose(s): 2.37x10\^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10\^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main inclusion Criteria:~* Must have pathologic documentation of non-small cell lung cancer, IB, II, IIIA.~* ECOG Performance Status of 0 - 1~* Bidimensionally measurable disease or evaluable disease~* Adequate organ function~Main exclusion Criteria:~* Have greater than Grade 1 neuropathy - motor/sensory~* Significant history of cardiac disease~* Pleural effusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: OTHER): None
- B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed FL.~* Documented CD20+ FL.~* Relapsed or refractory to any prior rituximab-containing regimen.~* Previously treated with a maximum of 4 cancer-directed treatment regimens.~* At least 1 measurable lesion \> 1.5 cm in at least 1 dimension by computed tomography or magnetic resonance imaging.~* Must be willing to undergo an incisional or excisional lymph node biopsy of accessible adenopathy or provide the most recent, available archived tumor biopsy.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.~Exclusion Criteria:~* Clinical evidence of transformation to a more aggressive subtype of lymphoma or Grade 3B FL.~* History of central nervous system lymphoma (either primary or metastatic).~* Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host disease following allogeneic transplant or autologous stem cell transplant within the last 3 months before the date of the first dose of study drug administration.~* Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug.~* Prior treatment with a selective PI3Kδ inhibitor or a pan PI3K inhibitor.~* Prior treatment with bendamustine (within 12 months of the start of study treatment). Subjects with prior bendamustine treatment (\> 12 months before the start of study treatment) are eligible if they meet the following criteria:~  * Did not discontinue because of tolerability concerns.~ * Achieved either partial or CR to the bendamustine regimen of at least 12 months in duration before relapse/progression.~ * Experienced progression following a regimen containing an alkylating agent.~* Received prior obinutuzumab.~* Received rituximab within 4 weeks of study start.~* Prior treatment-related toxicities that have not resolved to ≤ Grade 1 before the date of study drug administration except for stable chronic toxicities (≤ Grade 2) not expected to resolve (eg, stable Grade 2 peripheral neurotoxicity).~* Received any prior monoclonal antibody (except an anti-CD20 antibody) within 90 days before the date of study start.~* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (eg, subjects in whom re-administration with rituximab would be contraindicated for safety reasons).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parsaclisib + Hexal and Gazyvaro (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with diagnosis of chronic hepatitis C genotype 2 or 3~Exclusion Criteria:~* Patients with hepatitis genotype I and IV

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- chronic hepatitis C genotype 2 or 3 (Type: EXPERIMENTAL): In all patients Pegylated Interferon α2 (pegIFN) plus Ribavirin were given in standard doses. Peg-INF was given in a dose of 180 μg/week and ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Variceal Ligation in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for endoscopic variceal ligation cohort~* All paediatric patients (\< 18 years)~* Known chronic liver disease~* Suspicion of portal hypertension based on splenomegaly in the ultrasound, presence of collaterals in the abdominal wall or low platelet count (\<150.000 platelets/L),~* Grade 2 or 3 esophageal varices or red spots, regardless of the grade of the esophageal varices diagnosed by endoscopy~* From January 2014 to April 2017~Exclusion Criteria for endoscopic variceal ligation cohort:~* Patients initially treated with Non-selective beta blockers and subsequently treated with endoscopic variceal ligation as primary prophylaxis were excluded of the study.~* Patients for whom endoscopic variceal ligation was not feasible because of patients' weight/seize were also excluded of the study.~Inclusion Criteria for propranolol cohort~* All paediatric patients (\< 18 years)~* Known chronic liver disease~* Suspicion of portal hypertension based on splenomegaly in the ultrasound, presence of collaterals in the abdominal wall or low platelet count (\<150.000 platelets/L),~* Grade 2 or 3 esophageal varices or red spots, regardless of the grade of the esophageal varices diagnosed by endoscopy~* That received propranolol as primary prophylaxis~* From January 2009 to December 2013.~Exclusion Criteria propranolol cohort:~* Patients initially treated with non-selective beta blockers and subsequently treated with endoscopic variceal ligation as primary prophylaxis were excluded of the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Endoscopic Variceal Ligation (Type: None): From January 2014 to April 2017, all paediatric patients with a known chronic liver disease with suspicion of portal hypertension who presented grade 2 or 3 esophageal varices or red spots in the upper endoscopy received primary prophylaxis with endoscopic variceal ligation.
- Propranolol Group (Type: None): Patients in the Endoscopic Variceal Ligation group were compared with an historical cohort of 30 consecutive patients with portal hypertension and grade 2 or 3 esophageal varices or red spots who received propranolol as primary prophylaxis from January 2009 to December 2013. All patients were treatment-naïve in regards of their upper gastrointestinal bleeding prophylaxis at the time of the first upper endoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol~* Meet all of the following criteria in at least one eye: Have more than 10 lashes with collarettes present on the upper lid; have at least mild erythema of the upper eyelid margin; have an average Demodex density, upper and lower eyelids combined, of 1.5 or more mites per lash~Exclusion Criteria:~* Have used lid hygiene products within 14 days of Screening or unwilling to forego the use of lid hygiene products during the study~* Have worn contact lenses within 7 days of Screening or be unwilling to forego contact lens wear during the study~* Have used artificial eyelashes or eyelash extensions within 7 days of Screening or be unwilling to forego their use during the study~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
- Control (Type: PLACEBO_COMPARATOR): Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete